Abstract
Rheumatoid arthritis is a relatively common problem in women of reproductive age. Pregnancy may affect all aspects of the pharmacokinetics of the drugs used in its treatment. The effects of pregnancy on the pharmacokinetics of drugs are, for the most part, not clinically significant. The pharmacokinetics of placental transfer and fetal safety have been specified for many drugs. Drugs used in rheumatoid arthritis can be classified into 3 classes: those with the greatest safety for the fetus, those that are unsafe for the fetus, and those for which there are insufficient data to determine the risk to the fetus.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.